FDA SCHEDULES PRE-LICENSE INSPECTION OF REMESTEMCEL-L MANUFACTURING
Biologics License Application (BLA) Resubmission for Pediatric Acute Graft-Versus-Host
Disease (SR-aGVHD) Currently Being Reviewed
PDUFA Goal Date August 2, 2023
If Approved, Remestemcel-L will be the First Allogeneic “Off-the-Shelf” Cellular Medicine in
the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD
Melbourne, Australia; March 22 and New York, USA; March 21, 2023: Mesoblast Limited
(ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases,
today announced that, as part of the ongoing review of the BLA for remestemcel-L in the treatment of
children with SR-aGVHD, the United States Food and Drug Administration (FDA) has scheduled a PreLicense Inspection (PLI) of Mesoblast’s cell therapy manufacturing operations at Lonza Bioscience in
Singapore.
On March 7, 2023, the FDA accepted the Company’s resubmission of the BLA for remestemcel-L and set
a Prescription Drug User Fee Act (PDUFA) goal date of August 2, 2023.
Remestemcel-L has FDA Fast Track designation, a process to facilitate the development and expedited
review of therapies for serious conditions that fill unmet medical needs, and Priority Review designation,
which is given to drugs that treat a serious condition and provide a significant improvement in safety or
effectiveness over existing treatments. Survival outcomes have not improved over the past two decades
for children or adults with the most severe forms of SR-aGVHD.1-3 The lack of any approved treatments
for children under 12 means that there is an urgent need for a therapy that improves the dismal survival
outcomes in children.
“We are pleased that the pre-license inspection of our manufacturing operations has been scheduled.
We look forward to continuing to work closely with FDA during the review period with the aim to make
remestemcel-L available as a therapy for children suffering from SR-aGVHD,” said Mesoblast Chief
Executive Silviu Itescu.
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection, page-11
-
- There are more pages in this discussion • 265 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.17 |
Change
0.000(0.00%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.15 | $1.20 | $1.15 | $1.618M | 1.381M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 18060 | $1.17 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.17 | 16015 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 44140 | 1.175 |
13 | 102517 | 1.170 |
14 | 120595 | 1.165 |
10 | 97349 | 1.160 |
8 | 64460 | 1.155 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 27451 | 8 |
1.185 | 43161 | 11 |
1.190 | 219953 | 18 |
1.195 | 100133 | 11 |
1.200 | 92010 | 15 |
Last trade - 11.21am 16/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online